McAlpine J - Search Results

1

The histologic subtype of ovarian tumors affects the detection rate by pelvic washings.

Fadare O, Mariappan MR, Wang S, Hileeto D, McAlpine J, Rimm DL. Fadare O, et al. Among authors: mcalpine j. Cancer. 2004 Jun 25;102(3):150-6. doi: 10.1002/cncr.20239. Cancer. 2004. PMID: 15211473 Free article.

2

Brain metastases in epithelial ovarian and primary peritoneal carcinoma.

Ratner ES, Toy E, O'Malley DM, McAlpine J, Rutherford TJ, Azodi M, Higgins SA, Schwartz PE. Ratner ES, et al. Among authors: mcalpine j. Int J Gynecol Cancer. 2009 Jul;19(5):856-9. doi: 10.1111/IGC.0b013e3181a83301. Int J Gynecol Cancer. 2009. PMID: 19574773

3

Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.

Kelly MG, O'malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE. Kelly MG, et al. Among authors: mcalpine j. Gynecol Oncol. 2005 Sep;98(3):353-9. doi: 10.1016/j.ygyno.2005.06.012. Gynecol Oncol. 2005. PMID: 16005947

4

Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.

O'Malley DM, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, Rutherford T. O'Malley DM, et al. Among authors: mcalpine j. Gynecol Oncol. 2005 Aug;98(2):242-8. doi: 10.1016/j.ygyno.2005.04.032. Gynecol Oncol. 2005. PMID: 15992916

5

BRCA1 immunohistochemical staining as a prognostic indicator in uterine serous carcinoma.

Beirne JP, Quinn JE, Maxwell P, Kalloger SE, McAlpine J, Gilks CB, Harley IJ, McCluggage WG. Beirne JP, et al. Among authors: mcalpine j. Int J Gynecol Cancer. 2013 Jan;23(1):113-8. doi: 10.1097/IGC.0b013e3182798188. Int J Gynecol Cancer. 2013. PMID: 23221734

6

Quality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action!

Joly F, McAlpine J, Nout R, Åvall-Lundqvist E, Shash E, Friedlander M; Gynaecologic Cancer InterGroup (GCIG). Joly F, et al. Among authors: mcalpine j. Int J Gynecol Cancer. 2014 Nov;24(9):1693-9. doi: 10.1097/IGC.0000000000000299. Int J Gynecol Cancer. 2014. PMID: 25340294

7

First-line therapy in ovarian cancer trials.

Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Thigpen T, et al. Among authors: mcalpine j. Int J Gynecol Cancer. 2011 May;21(4):756-62. doi: 10.1097/IGC.0b013e31821ce75d. Int J Gynecol Cancer. 2011. PMID: 21543937 Review.

8

Teaching cervical cancer surgery in low- or middle-resource countries.

Elit LM, Rosen B, Jimenez W, Giede C, Cybulska P, Sinasac S, Dodge J, Ayush E, Omenge O, Bernardini M, Finlayson S, McAlpine J, Miller D; International Community of Practice Committee of the Society of Gynecologic Oncology of Canada. Elit LM, et al. Among authors: mcalpine j. Int J Gynecol Cancer. 2010 Dec;20(9):1604-8. Int J Gynecol Cancer. 2010. PMID: 21370604

9

Does MMR status in endometrial cancer influence response to adjuvant therapy?

Kim SR, Pina A, Albert A, McAlpine J, Wolber R, Blake Gilks C, Kwon JS. Kim SR, et al. Among authors: mcalpine j. Gynecol Oncol. 2018 Oct;151(1):76-81. doi: 10.1016/j.ygyno.2018.08.020. Epub 2018 Aug 29. Gynecol Oncol. 2018. PMID: 30172479

10

Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival.

Bernard B, Clarke BA, Malowany JI, McAlpine J, Lee CH, Atenafu EG, Ferguson S, Mackay H. Bernard B, et al. Among authors: mcalpine j. Gynecol Oncol. 2013 Dec;131(3):634-9. doi: 10.1016/j.ygyno.2013.09.011. Epub 2013 Oct 14. Gynecol Oncol. 2013. PMID: 24135678

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

425 results

Search Page